Multimodal Program for Cancer Related Cachexia Prevention

Launched by CYPRUS UNIVERSITY OF TECHNOLOGY · Nov 7, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a special program designed to help prevent a condition called cancer-related cachexia, which is a syndrome that causes weight loss and muscle wasting in cancer patients. The goal is to see how effective this program is in supporting both patients receiving treatment for certain types of cancer and their family caregivers. The trial is currently recruiting participants aged 18 and older who have been diagnosed with solid tumors, such as those in the stomach, colorectal area, pancreas, breast, or lungs, and who are undergoing various treatments like chemotherapy or immunotherapy.

To be eligible, participants should not have blood cancers, need to be able to bring a family caregiver to support them, and should be in relatively good shape health-wise, meaning they shouldn't have significant weight loss or severe physical limitations. If you or someone you know is interested in participating, you can expect to receive education and support aimed at preventing weight loss and improving overall well-being during cancer treatment. It's also important to note that participants must be able to read and understand Greek or English.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 years old or older
• • 2. Participants must be diagnosed with solid tumour (stomach, colorectal, pancreas, breast, lung)
• • 3. Participants needing chemotherapy/immunotherapy/hormone therapy/target therapy
• • 4. Participants must be normal or pre cachectic as defined by the guidelines
• • 5. Read and understand Greek or English
• Exclusion Criteria:
• • 1. Haematologic tumors
• • 2. Parenteral Nutrition
• • 3. ECOG Performance status \>2 or Karnofsky Performance Status \<60%
• • 4. Participant who can not introduce a family caregiver
• 5. Participants in cachexia or refractory cachexia stage as defined by the guidelines below:
• • \>5% weight loss over the past 6 months (in absence of simple starvation); OR
• • BMI \<20 and any degree of weight loss \>2%; OR
• • Appendicular skeletal muscle index consistent with sarcopenia (whole body fat-free mass index without bone determined by bioelectrical impedance (men \<14.6 kg/m²; women \<11.4 kg/m²) and weight loss \>2%
• • 6. Patients who use complementary therapies (ex-acupuncture)